Dr. Daniel LabowFocus: Peritoneal Mesothelioma
Mount Sinai Hospital Surgical Oncology
1470 Madison Ave.
New York, NY
Dr. Daniel Labow established and directs one of the busiest hyperthermic intraperitoneal chemotherapy (HIPEC) programs in the country. He has performed over 220 HIPEC procedures.
About Dr. Labow
Dr. Labow is the Chief of Surgical Oncology at Mount Sinai Hospital and has been with them since 2004. He founded Mount Sinai’s HIPEC program in 2007. Since then, he has watched the program grow quickly due to their effort and success in treating peritoneal mesothelioma with HIPEC.
Medical Degree and Residencies
M.D., Brown University, 1995. Dr. Labow completed residency in general surgery at University of Chicago Hospitals. He also completed a fellowship in surgery oncology at Memorial Sloan Kettering Cancer Center.
Associate Professor of Surgery and Fellowship Program Director, Surgical Oncology, Icahn School of Medicine at Mount Sinai.
Dr. Labow comes from a family of medical professionals. His father was a physician, his mother was a biochemist and his brother is a pediatric surgeon.
Only 400 to 500 peritoneal mesothelioma cases are diagnosed each year. Dr. Labow calculates that he sees about 10 to 20 of those peritoneal mesothelioma patients a year. When he is not treating patients, Dr. Labow works hard to advance the educational program at Mount Sinai Hospital, where he is the program director of surgical oncology.
Dr. Labow’s Accomplishments
- Named one of the best doctors of 2013 by New York Magazine
- Named one of the New York metro area’s top doctors by Castle Connolly
- Recipient of Patients’ Choice Award (2008-2012, 2014)
Get Connected To Dr. Daniel Labow
Why Choose Dr. Labow?
- Performed over 220 HIPEC procedures with cytoreduction
- Minimally-invasive treatment options
- Communicative and compassionate
Dr. Labow's Research and Treatments
During his training and for two years after his residency, Dr. Labow pursued extensive clinical and scientific research. His clinical and research interests include the diagnosis and treatment of malignancies like peritoneal mesothelioma.
“I think that as we learn more and more about these diseases, how they start, identifying them on a genetic level, really profiling patients and categorizing and personalizing their care, we can really impact patients more directly,” said Dr. Labow.
Dr. Labow’s dedication to research and training allow him to understand all the treatments available for abdominal cancer, including investigational approaches. He also concentrates on the use of minimally invasive techniques in cancer care and promotes a multidisciplinary approach to therapy.
Dr. Labow and HIPEC
Dr. Labow strongly advocates HIPEC for patients with late stage and difficult to treat cancer due to its ability to improve outcomes and survival rates.
“It’s quite unique in combating cancer and getting improved outcomes for patients who often only had months to live. We are getting patients that usually survive only months and are now living multiple years,” Dr. Labow said. “That is a small step, and certainly there is more room to grow. But it’s taking patients that didn’t have options and giving them more.”
While HIPEC can be appropriate for a wide variety of patients, in general, the cancer needs to be limited to the abdominal cavity for HIPEC to be used, Dr. Labow explained, adding that it can be combined with traditional chemotherapy as well.
He cautions that patients must be generally healthy to undergo HIPEC with cytoreduction, as the procedure can be long and complex. Another key to HIPEC treatment is the need to be able to remove all of the visible cancer and then administer the chemotherapy. If the disease is too extensive then HIPEC may not be possible.
Want a referral to see Dr. Labow? Check out our free Doctor Match program.